X4 Pharmaceuticals (NASDAQ:XFOR) Price Target Cut to $8.50 by Analysts at HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) had its price objective lowered by analysts at HC Wainwright from $11.00 to $8.50 in a research note issued on Friday, The Fly reports.

A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of X4 Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 17th. Canaccord Genuity Group cut their target price on shares of X4 Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, April 5th. Canaccord Genuity Group cut their target price on shares of X4 Pharmaceuticals from $20.00 to $10.00 in a research note on Tuesday, April 5th. Finally, Stifel Nicolaus cut their target price on shares of X4 Pharmaceuticals from $19.00 to $10.00 in a research note on Thursday, March 17th.

Shares of XFOR opened at $1.04 on Friday. The stock has a market capitalization of $32.06 million, a PE ratio of -0.26 and a beta of 0.62. X4 Pharmaceuticals has a 1 year low of $1.00 and a 1 year high of $9.90. The company has a debt-to-equity ratio of 0.51, a quick ratio of 6.27 and a current ratio of 6.27. The company’s 50-day simple moving average is $1.62 and its 200-day simple moving average is $2.47.

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.10). During the same period last year, the business earned ($1.30) EPS. On average, sell-side analysts predict that X4 Pharmaceuticals will post -2.53 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp purchased a new position in X4 Pharmaceuticals in the first quarter valued at approximately $246,000. Minot Wealth Management LLC acquired a new stake in shares of X4 Pharmaceuticals in the first quarter valued at approximately $96,000. Norges Bank acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $63,000. Goldman Sachs Group Inc. boosted its holdings in shares of X4 Pharmaceuticals by 100.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 20,949 shares of the company’s stock valued at $48,000 after acquiring an additional 10,474 shares during the period. Finally, Kennedy Capital Management Inc. acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $301,000. Institutional investors own 76.63% of the company’s stock.

About X4 Pharmaceuticals (Get Rating)

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.

See Also